Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene DDR2
Variant I638F
Impact List missense
Protein Effect gain of function
Gene Variant Descriptions DDR2 I638F lies within the protein kinase domain of the Ddr2 protein (UniProt.org). I638F confers a gain of function to the Ddr2 protein, as demonstrated by increased Ddr2 phosphorylation (PMID: 28161936) and Stat5 activation and transformation of cultured cells, and induced tumor formation in mouse xenograft models (PMID: 22328973).
Associated Drug Resistance

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Transcript NM_001014796
gDNA chr1:g.162775707A>T
cDNA c.1912A>T
Protein p.I638F
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_006182 chr1:g.162775707A>T c.1912A>T p.I638F RefSeq GRCh38/hg38
XM_011509586 chr1:g.162775707A>T c.1912A>T p.I638F RefSeq GRCh38/hg38
XM_011509587 chr1:g.162775707A>T c.1912A>T p.I638F RefSeq GRCh38/hg38
XM_006711344 chr1:g.162775707A>T c.1912A>T p.I638F RefSeq GRCh38/hg38
NM_001014796 chr1:g.162775707A>T c.1912A>T p.I638F RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
DDR2 I638F DDR2 T654M lung squamous cell carcinoma decreased response Dasatinib Preclinical Actionable In a preclinical study, expression of DDR2 T654M in lung squamous cell cancer cells harboring DDR2 I638F resulted in decreased sensitivity to Sprycel (dasatinib) in culture (PMID: 22328973). 22328973
DDR2 I638F Advanced Solid Tumor sensitive Nilotinib + Saracatinib Preclinical Actionable In a preclinical study, the combination of Saracatinib (AZD0530) and Tasigna (nilotinib) reduced proliferation of transformed cells expressing DDR2 I638F in culture, with increased potency over either agent alone (PMID: 22328973). 22328973
DDR2 I638F lung squamous cell carcinoma sensitive Dasatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Sprycel (dasatinib) inhibited growth of a lung squamous cell carcinoma cell line harboring a DDR2 I638F mutation in culture and in xenograft models (PMID: 22328973). 22328973
DDR2 I638F Advanced Solid Tumor sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 I638F in culture (PMID: 22328973). 22328973
DDR2 I638F Advanced Solid Tumor sensitive Dasatinib Preclinical Actionable In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 I638F in culture (PMID: 22328973). 22328973
DDR2 I638F lung squamous cell carcinoma sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited proliferation of lung squamous cell carcinoma cells harboring a DDR2 I638F mutation in cell culture (PMID: 22328973). 22328973
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
DDR2 act mut lung non-small cell carcinoma sensitive Lucitanib Preclinical Actionable In a preclinical study, Lucitanib (E-3810) decreased DDR2 phosphorylation, and inhibited proliferation and induced apoptosis in lung squamous cell carcinoma cells harboring a DDR2 activating mutation in culture (PMID: 24696502). 24696502
DDR2 mutant lung squamous cell carcinoma sensitive Dasatinib Preclinical Actionable In a preclinical study, lung squamous cell cancer cells harboring DDR2 mutations demonstrated sensitivity to Sprycel (dasatinib) in culture (PMID: 22328973). 22328973
Molecular Profile Protein Effect Treatment Approaches
DDR2 I638F DDR2 T654M
DDR2 I638F gain of function DDR2 inhibitor